ストックスクリーナーアプリを入手
30.33
1.71%
0.48
前日終値:
$29.85
開ける：
$30.22
24時間の取引高:
41,426
Relative Volume:
0.03
時価総額：
$2.52B
収益：
-
当期純損益:
$-154.65M
株価収益率:
-12.75
EPS:
-2.3786
ネットキャッシュフロー:
$-142.43M
1週間 パフォーマンス:
+16.63%
1か月 パフォーマンス:
+10.36%
6か月 パフォーマンス:
-29.98%
1年 パフォーマンス:
+90.23%
1日の値動き範囲:
$30.07
$30.69
1週間の範囲:
$26.50
$30.60
52週間の値動き範囲:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
30.50 | 2.46B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
437.50 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.27 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.62 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.94 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | TD Cowen | Buy |
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Technical Reactions to MLYS Trends in Macro Strategies - Stock Traders Daily
Mineralys Therapeutics shareholders approve director elections and auditor at annual meeting - Investing.com Canada
Mineralys Therapeutics (MLYS) 2026 meeting approves directors and auditor - Stock Titan
Mineralys Therapeutics Stock Surges on Trial Hopes - TipRanks
Mineralys CMO David Rodman sells $11,488 in shares By Investing.com - Investing.com Canada
Mineralys CMO David Rodman sells $11,488 in shares - Investing.com
Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares - Stock Titan
Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48 - Moomoo
417‑share proposed sale by Mineralys (NASDAQ: MLYS) via cashless exercise - Stock Titan
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) - The Manila Times
Mineralys Therapeutics announces presentation of new data from the late-stage launch-htn trial of lorundrostat - marketscreener.com
Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat - TradingView
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56 - Moomoo
Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks
Mineralys Advances Hypertension Drug Toward FDA Decision - MyChesCo
Mineralys Therapeutics (Nasdaq: MLYS) Grants Equity Awards to New Hires - MyChesCo
Mineralys Therapeutics Insider Sold Shares Worth $652,638, According to a Recent SEC Filing - Moomoo
Trading the Move, Not the Narrative: (MLYS) Edition - Stock Traders Daily
Mineralys CMO Rodman sells $652,637 in company stock By Investing.com - Investing.com Australia
David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys CMO Rodman sells $652,637 in company stock - Investing.com UK
Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan - Stock Titan
Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS) - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Vanguard Group Inc. - MarketBeat
Mineralys (MLYS) Q1 2026 Earnings Transcript - AOL.com
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
MLYS: Lorundrostat advances toward FDA approval with strong clinical data and launch readiness - TradingView
MLYS: NDA accepted for lorundrostat; launch prep and strong cash position support U.S. commercialization - TradingView
TradingKey - TradingKey
How FDA NDA Acceptance for Lorundrostat At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story - Yahoo Finance
HC Wainwright Issues Pessimistic Forecast for MLYS Earnings - MarketBeat
Mineralys outlines lorundrostat US launch plans ahead of December 22, 2026 PDUFA - MSN
Mineralys Therapeutics, Inc. $MLYS Stock Holdings Lessened by Swedbank AB - MarketBeat
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54 - Moomoo
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Mineralys Therapeutics Maps Path After Lorundrostat NDA - TipRanks
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move - Seeking Alpha
Mineralys Therapeutics, Inc. Q1 2026 Financials: Lorundrostat Clinical Progress and Key SEC Filings - Minichart
Mineralys Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Mineralys Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
MLYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings call transcript: Mineralys Therapeutics beats Q1 2026 EPS estimates By Investing.com - Investing.com Australia
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):